> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Revive Therapeutics Get Orphan Status for Cannabidiol
- URL: https://www.fdaweb.com/revive-therapeutics-get-orphan-status-for-cannabidiol/
- Published: 2018-06-27T12:00:00.000Z
- Updated: 2026-09-15T00:16:13.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141784

FDA has granted Revive Therapeutics an orphan drug designation for cannabidiol (CBD) for treating autoimmune hepatitis (AIH), a rare disease that causes inflammation to the liver. The current standard of care is the use of steroids alone or steroids combined with azathioprine, which can cause severe treatment-related side effects in 13% of patients treated, treatment failure in 9%, and incomplete response in 13%, according to the company. “Therefore, given the unwanted outcomes associated with a steroid-based therapy, an alternative steroid-free treatment option such as CBD, with its known safety profile, may provide a potential solution for an improved treatment strategy for those patients unresponsive to, intolerant of, or non-adherent with a steroid-based therapy for AIH.”